Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Diane Durecki"'
Autor:
Patricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, Winnie S Liang, John Carpten, David W Craig, David B Solit, Alan H Bryce, Jeffrey A Kiefer, Jessica Aldrich, Sara Nasser, Rebecca Halperin, Sara A Byron, Mary Jo Pilat, Scott A Boerner, Diane Durecki, William P D Hendricks, Daniel Enriquez, Tyler Izatt, Jonathan Keats, Christophe Legendre, Svetomir N Markovic, Amy Weise, Fatima Naveed, Jessica Schmidt, Gargi D Basu, Shobana Sekar, Jonathan Adkins, Erica Tassone, Karthigayini Sivaprakasam, Victoria Zismann, Valerie S Calvert, Emanuel F Petricoin, Leslie Anne Fecher, Christopher Lao, J Paul Eder, Nicholas J Vogelzang, Jane Perlmutter, Mark Gorman, Barbara Manica, Lisa Fox, Nicholas Schork, Daniel Zelterman, Michelle DeVeaux, Richard W Joseph, C Lance Cowey, Jeffrey M Trent
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0248097 (2021)
Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-
Externí odkaz:
https://doaj.org/article/ea286e5ad5d3466fb04534c8639561db
Autor:
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Jing Li, Diane Durecki, Jan Drappatz, Vinay Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, S. Percy Ivy, Ranjit S. Bindra, Antonio Omuro, Patricia LoRusso
Publikováno v:
Cancer Research Communications. 3:192-201
Purpose: Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations (IDH1/2mt) are frequent in glioma. Preclinical studies suggest IDH1/2mts confer “BRCAness” phenotype, a vulnerability that can be targeted through PARP inhibition. To test this hypothes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f49e5afc6bbf0633b5b460924fa41470
https://doi.org/10.1158/2767-9764.crc-22-0436
https://doi.org/10.1158/2767-9764.crc-22-0436
Autor:
Patricia LoRusso, Antonio Omuro, Ranjit S. Bindra, S. Percy Ivy, Pierre Giglio, Javier Gonzalez, Frank Scott Lieberman, Vinay Puduvalli, Jan Drappatz, Diane Durecki, Jing Li, Scott Boerner, Yu Shyr, Derek Shyr, Mary Jo Pilat, Kristina Fanucci
Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0df51c6bc3f4ac79ca4a3c83d4e7c11
https://doi.org/10.1158/2767-9764.22545912.v1
https://doi.org/10.1158/2767-9764.22545912.v1
Autor:
Patricia LoRusso, Antonio Omuro, Ranjit S. Bindra, S. Percy Ivy, Pierre Giglio, Javier Gonzalez, Frank Scott Lieberman, Vinay Puduvalli, Jan Drappatz, Diane Durecki, Jing Li, Scott Boerner, Yu Shyr, Derek Shyr, Mary Jo Pilat, Kristina Fanucci
Definition of Progression, Tumor Classification, and Eligibility Criteria, retreatment criteria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38051cb61c7f9e35bbffa7887c372133
https://doi.org/10.1158/2767-9764.22545915
https://doi.org/10.1158/2767-9764.22545915
Autor:
Patricia LoRusso, Antonio Omuro, Ranjit S. Bindra, S. Percy Ivy, Pierre Giglio, Javier Gonzalez, Frank Scott Lieberman, Vinay Puduvalli, Jan Drappatz, Diane Durecki, Jing Li, Scott Boerner, Yu Shyr, Derek Shyr, Mary Jo Pilat, Kristina Fanucci
Purpose:Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations (IDH1/2mt) are frequent in glioma. Preclinical studies suggest IDH1/2mts confer “BRCAness” phenotype, a vulnerability that can be targeted through PARP inhibition. To test this hypothesi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::770e848003c7826eb1665f7c2268edfc
https://doi.org/10.1158/2767-9764.c.6551052
https://doi.org/10.1158/2767-9764.c.6551052
Autor:
Kristina A. Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A. Boerner, Diane Durecki, Anne Noonan, Vandana Abramson, Cesar Santa-Maria, Hyo Han, Rita Nanda, Elizabeth Claire Dees, Haeseong Park, Saundra Buys, Namrata Peswani, Helen Chew, Hadeel Assad, Gerburg Wulf, Angelique Richardson, Meghna S. Trivedi, Adam Brufsky, James Abbruzzese, Anosheh Afghahi, Elad Sharon, Kurt Schalper, Patricia LoRusso
Publikováno v:
Cancer Research. 83:CT145-CT145
Background: Poly-ADP ribose polymerase inhibitors (PARPi) work by impairing DNA damage repair and have demonstrated activity in patients with BRCAmt breast cancer. Their mechanism of action leads to high mutational burden and increased neoantigens su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fb34e1efc236d28e689b7cc962ee27f
https://doi.org/10.1158/1538-7445.am2023-ct145
https://doi.org/10.1158/1538-7445.am2023-ct145
Autor:
Diane Durecki, David Craig, Tracy Bell, Shukmei Wong, Jessica Aldrich, Scott A. Boerner, Mary Jo Pilat, Sara M. Tolaney, Robert J. Kinders, Lihua Wang, Dongpo Cai, Adam Bowditch, John D. Carpten, Alice P. Chen, Tina Guthrie, Geoffrey I. Shapiro, Patricia LoRusso, Lance K. Heilbrun, Ralph E. Parchment
Publikováno v:
Cancer Research. 75:CT325-CT325
Background: The nuclear enzyme PARP is essential in recognition and repair of DNA damage. Preclinical evidence suggests that PARP inhibitors work as sensitizing agents for DNA-damaging agents such as irinotecan. Veliparib is an orally bioavailable PA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::819a203c2242635ff857de2f3d582c15
https://doi.org/10.1158/1538-7445.am2015-ct325
https://doi.org/10.1158/1538-7445.am2015-ct325